Welcome to our dedicated page for Freenome news (Ticker: FRNM), a resource for investors and traders seeking the latest updates and insights on Freenome stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Freenome's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Freenome's position in the market.
Freenome (Nasdaq: FRNM) announced the closing of its business combination with Perceptive Capital Solutions Corp, creating a combined company renamed Freenome that is expected to begin trading on the Nasdaq Capital Market on July 21, 2026 under ticker FRNM.
The transaction is expected to deliver approximately $310 million in gross proceeds, including about $70 million from the former PCSC trust account and a fully committed $240 million PIPE led by Perceptive Advisors and RA Capital, with participation from several other healthcare investors. According to Freenome, this capital will support its blood-based early cancer detection portfolio, AI/ML-enabled multiomics platform, and commercialization efforts, including colorectal and lung cancer programs and more than 10 additional indications. The company outlines three focus pillars: advancing its comprehensive cancer detection portfolio, enhancing its AI-enabled multiomics platform, and scaling commercial, lab and digital infrastructure, supported by partnerships with Abbott and Roche.